Drug targeting to the brain - a review

Current Nanoscience

Volumn 7, Issue 1, 2011, Pages 21-36

  Jain, Aviral ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Blood brain barrier; Brain capillary endothelial cells; Colloidosomes; Dendrimers; Liposomes; Polymeric nanoparticles; Solid lipid nanoparticles

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELLS; COLLOIDOSOMES; POLYMERIC NANOPARTICLES; SOLID LIPID NANOPARTICLES;

BLOOD; BLOOD VESSELS; CHEMICAL MODIFICATION; DENDRIMERS; DRUG DELIVERY; ENDOTHELIAL CELLS; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS; SELF ASSEMBLY;

BRAIN;

ALGINIC ACID; ALKYL GROUP; AMPHOTERICIN B LIPID COMPLEX; BRADYKININ; CARMUSTINE; CHITOSAN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; GELATIN; GLYCEROL DERIVATIVE; GLYCOPROTEIN P; HYBRID PROTEIN; LEUKOTRIENE C4; LIPOSOME; MACROGOL; MANNITOL; MICROSPHERE; NANOPARTICLE; NEUROPEPTIDE; POLYASPARTIC ACID; POLYCAPROLACTONE; POLYESTER; POLYGLACTIN; POLYMER; POLYSACCHARIDE; PRODRUG; SOLID LIPID NANOPARTICLE; UNINDEXED DRUG;

ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN; BRAIN CAPILLARY; CATHETER; CELL CULTURE; CELL FREE SYSTEM; CHEMICAL MODIFICATION; CLINICAL TRIAL; COCULTURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; INFECTION; MINIPUMP; NONHUMAN; PARTITION COEFFICIENT; PERICYTE; POLYMERIZATION; PRIORITY JOURNAL; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 79551665471     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341311794480255     Document Type: Article

References (189)

1. Schlosshauer, B. The blood brain barrier: morphology, molecules and neurothelin. Bioassays, 1993, 15, 341-346.
2. Ricci, M.; Blasi, P.; Giovagnoli, S.; Rossi, C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr. Med. Chem., 2006, 13, 1757-1775.
3. Zlokovic, B.V. The blood brain barrier in health and chronic neurodegenerative disorders. Neuron Cambridge MA, 2008, 57, 178-201.
4. Silberberg, D. Neurological disease in the global agenda. Ann. Neurol., 2008, 64, 475-476.
5. Enrlich, P. Uber die Beziehungen von chemische constitution, vertheilung, uns pharmakologischer wirkung, collected studies in immunity, Repr and Trans Wiley: New York, 1906; pp. 567-595.
6. Goldmann, E.E.; Vitafarbung, Z. Abh preuss akad wiss. Phys-Math, 1913, 1, 1-60.
7. Stern, L.; Gautier, R. Les repports enter le liquide cephalo-rachidien et les elements nerveux de I'axe cerebrospinal. Arch. Intern. Physiol., 1922, 17, 391-448.
8. Friedemann, U. Blood-brain barrier. Physiol. Rev., 1942, 22, 125-145.
9. Broman, T. On basic aspects of the blood-brain barrier. Acta. Psychiatr. Neurol. Scand., 1955, 30(1-2), 115-124.
10. Reese, T. S.; Karnovsky, M. J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell. Biol., 1967, 34, 207-217.
11. Brightman, M. W.; Klatzo, I.; Olsson, Y.; Reese, T. S. The blood-brain barrier to proteins under normal and pathological conditions. J. Neurol. Sci., 1970, 10, 215-239.
12. Pardridge, W. M. Isolated brain capillaries: an in vitro model of blood brain barrier research. In: Introduction to the Blood Brain Barrier: Methodology, Biology and Pathology. Pardridge, W.M. Ed. Cambridge University Press: Cambridge, UK, 1998; pp. 49-61.
13. McComb, J.G.; Ziokovic, B.N. Cerebrospinal fluid and blood brain interface. In: Cheek, W.R.; Martin, A.K.; Mc Lone, D.G.; Reigal, D.H.; Walker, M.L., Eds. Pediatric Neurosurgery, W.B., Saunders Co., Philadelphia, 1994; p. 167.
14. Pardridge, W.M. Brain drug delivery and blood brain barrier transport. Drug Deliv., 1993, 1, 83-101.
15. Cancilla, P. A.; Bready, J.; Berliner, J. Brain endothelial astrocyte interactions. In: Pardridge, W.M. Ed. The blood brain barrier cellular and molecular biology, Raves press: New York, 1993, p. 25.
16. Brightman, W. M. Morphology of blood brain interface. Exp. Eye Res., 1997, 25, 1-25.
17. Frank, R. A.; Markou, A.; Wiggins, L. L. A systematic evaluation of the properties of train duration response functions. Behav. Neurosci., 1987, 101, 546-559.
18. Antonelli-Orlidge, A.; Saunders, K. B.; Smith, S. R.; D'Amore, P. A. An activated form of transforming growth factorbeta is produced by cocultures of endothelial-cells and pericytes. Proc. Natl. Acad. Sci., 1989, 86, 4544-4548.
19. Hellstrom, M.; Gerhardt, H.; Kalen, M.; Li, X.; Eriksson, U.; Wolburg, H.; Betsholts, C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell. Biol., 2001, 153, 543-554.
20. Coomber, B. L.; Stewart, P. A. Morphometric analysis of CNS microvascular endothelium. Microvasc. Res., 1985, 30, 99-115.
21. Herman, I. M. Microvascular Pericytes in development and diseases. In: Paradrige, W.M. Eds. The blood brain barrier, cellular and molecular biology, Raves press: New York, 1993, p. 1276.
22. Minakawa, T.; Bready, J.; Berliner, J.; Fisher, M.; Cancilla, P. A. In vitro interaction of astrocytes and pericytes with capillary-like structures of brain microvessel endothelium. Lab. Invest., 1991, 65, 32-40.
23. Hynes, R. O. Specificity of cell adhesion in development: the cadherin superfamily. Curr. Opin. Genet. Dev., 1992, 2, 621-624.
24. Wolburg, H.; Rohlmann, A. Structure-function relationships in gap junctions. Int. Rev. Cytol., 1995, 157, 315-373.
25. Tontsch, U.; Bauer, H. C. Glial cells and neurons induce blood-brain barrier related enzymes in cultured cerebral endothelial cells. Brain Res., 1991, 539(2), 247-253.
26. Brightman, M. Ultrastructure of brain endothelium. In: Bradbury, M.W.B. Ed. Physiology and pharmacology of the blood-brain barrier. Handbook of experimental pharmacology 103, Springer-Verlag, Berlin 1992, pp. 1-22.
27. Crone, C.; Christensen, O. Electric resistance of a capillary endothelium. J. Gen. Physiol., 1981, 77, 349-371.
28. Butt, A.; Jones, H. C.; Abbott, N. J. Electric resistance across the Blood Brain Barrier in anaesthezed rat: a developmental study. J. Physiol., 1990, 429, 47-62.
29. Hirase, T.; Hirase, T.; Staddon, J. M.; Saitou, M.; Ando-Akatsuka, Y.; Itoh, M.; Furuse, M.; Fujimoto, K.; Tsukita, S.; Rubin, L. L. Occludin as a possible determinant of tight junction permeability in endothelial cells. J. Cell. Sci., 1997, 110, 1603-1613.
30. Furuse, M.; Sasaki, H.; Tsukita, S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol., 1999, 147, 891-903.
31. Martìn-Padura, I.; Lostaglio, S.; Schneemann, M.; Williams, L.; Romano, M.; Fruscella, P.; Panzeri, C.; Stoppacciaro, A.; Ruco, L.; Villa, A.; Simmons, D.; Dejana, E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J. Cell Biol., 1998, 142, 117-127.
32. Borison, H. L.; Wang, S. C. Physiology and pharmacology of vomiting. Pharmacol. Rev., 1953, 5, 193-230.
33. Davson, H.; Segal, M. B. Morphology barriers of the barriers. In: Davson H, Segal MB eds. Physiology of the CSF and blood-brain barrier. CRC Press: Boca Raton 1995, pp. 93-192.
34. Davson, H.; Segal, M. B. Physiology of the CSF and blood-brain barrier. CRC Press: Boca Raton 1995, pp. 1-10.
35. Nabeshima, S.; Reese, T. S.; Landis, D. M.; Brightman, M. W. Junctions in the meninges and marginal glia. J. Comp. Neurol., 1975, 164, 127-169.
36. Brightman, M. W. The intracerebral movement of proteins injected into blood and cerebrospinal fluid of mice. Prog. Brain Res., 1968, 29, 19-40.
37. Egleton, R. D.; Davis T. P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides, 1997, 18(9), 1431-1439.
38. Blasberg, R. G.; Febsternacher, J. D.; Patlak, C. S. Transport of α-aminoosobutyric acid across brain capillary and cellular membranes. J. Cereb. Blood Flow Metab., 1983, 3, 8-32.
39. Davson, H. A comparative study of the aqueous humor and cerebrospinal fluid in the rabbit. J. Physiol., 1971, 218, 337-351.
40. Rapoport, S. I.; Ohno, K.; Pettigrew, K. D. Drug entry into the brain. Brain Res., 1979, 172, 354-359.
41. Takasato, Y.; Rapoport, S. I.; Smith, Q. R. An in situ brain perfusion technique by study cerebrovascular port in the rat. Am. J. Physiol., 1984, 247, H484-H493.
42. Crone, C. The permeability of brain capillaries to non-electrolytes. Acta Physiol. Scand., 1965, 64, 407-417.
43. Gjedde, A.; Deimer, N. H. Double-tracer study of the regional blood glucose transfer in the rat by computer assisted autoradiography. J. Cereb. Blood Flow Metab., 1985, 5, 282-289.
44. Gjedde, A.; Rasmussen, M. Blood brain glucose transport in the conscious rat: Comparison of the intravenous and intracarotid injection methods. J. Neurochem., 1980, 35, 1375-1381.
45. Bradbury, M. W. B.; Patlak, C. S.; Oldendorf, W. H. Analysis of brain uptake and loss of radiotracers after intracarotid injection. Am. J. Physiol., 1975, 229, 1110-1115.
46. Patlak, C. S.; Fenstermacher, J. D. Measurements of dog blood brain transfer constants by ventriculocisternal perfusion. Am. J. Physiol., 1975, 40, 458-463.
47. Joo, F. The blood brain barrier in vitro: the second decade. Neurochem. Int., 1993, 23, 499-521.
48. Lasbennes, F.; Gayet, J. Capacity for energy metabolism in microvessels isolated from rat brain. Neurochem. Res., 1984, 9, 1-10.
49. Osburg, B.; Peiser, C.; Domling, D.; Schomburg, L.; Ko, Y. T.; Voigt, K. Effect of endotoxin on expression of TNF receptors and transport of TNF-α at the blood brain barrier of the rat. Am. J. Physiol. Endocrinol. Metab., 2002, 283, E899-E908.
50. Pardridge, W. M. Blood brain barrier carrier mediated transport and brain metabolism of amino acids. Neurochem. Res., 1998, 23, 635-644.
51. Huwyler, J.; Pardridge, W. M. Examination of blood brain barrier transferring receptor by confocal laser scanning microscopy of unfixed isolated rat brain capillaries. J. Neurochem., 2000, 58, 1357-1367.
52. Gumbleton, M.; Audus, K. L. Progress and limitations in the use of in vitro cell cultures to serve as permeability screen for the blood-brain barrier. J. Pharm. Sci., 2001, 90, 1681-1698.
53. Reichel, A.; Begley, D. J.; Abbott, N. J. An overview of in vitro techniques for blood-brain barrier studies. Methods Mol. Med., 2003, 89, 307-324.
54. Audus, K. L.; Rose, J.M.; Wang, W.; Borchardt, R.T. Brain microvessel endothelia cell culture systems. In: Introduction to the blood brain barrier: methodology, biology and pathology (Pardridge WM), Cambridge, Cambridge University Press: UK, 1998, pp. 86-93.
55. Patlak, C. S.; Paulson, O. B. The role of unstirred layers for water exchange across the blood-brain barrier. Microvasc. Res., 1981, 21, 117-127.
56. Méresse, S.; Dehouck, M. P.; Delorme, P.; Bensaid, M.; Tauber, J. P.; Delbart, C.; Fruchart, J. C.; Cecchelli, R. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J. Neurochem., 1989, 53, 1363-1371.
57. Lundquist, S.; Renftel, M.; Brillault, J.; Fenart, L.; Cecchelli, R.; Dehouck, M. P. Prediction of drug transport through the blood-brain barrier in vivo: a comparison between two in vitro cell models. Pharma. Res., 2002, 7, 976-981.
58. Hoheisel, D.; Nitz, T.; Franke, H.; Wegener, J.; Hakvoort, A.; Tilling, T.; Galla, H. J. Hydrocortisone reinforces the blood-brain barrier properties in a serum-free cell culture system. Biochem. Biophys. Res. Comm., 1998, 244, 231-316.
59. Kramer, S. D.; Schutz, Y. B.; Wunderli-Allenspach, H.; Abbott, N. J.; Begley, D. J. Lipids in blood-brain barrier models in vitro. II. Influence of glial cells on lipid classes and lipid fatty acids. In vitro Cell. Dev. Biol. Anim., 2002, 38, 566-571.
60. Tähti, H.; Nevala, H.; Toimela, T. Refining in vitro neurotoxicity testing-the development of blood-brain barrier models. Altern. Lab. Anim., 2003, 31, 273-276.
61. Telling, T. H.; Engelbertz, C. H.; Decker, S. T.; Karte, D.; Huwel, S.; Galla, H. J. Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell culture. Cell Tissue Res., 2002, 310, 19-29.
62. Toimela, T.; Maenpää, H.; Mannerström, M.; Tähti, H. Development of an in vitro blood-brain barrier model-cytotoxicity of mercury and aluminum. Toxicol. Appl. Pharmacol., 2004, 195, 73-82.
63. Neuwelt, E. A.; Barnett, P. A.; Ramsey, F.; Hellstrom, K. E.; Hellstrom, I.; McCormick, C. L. Effect of blood brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenograft. J. Nucl. Med., 1994, 35, 1831-1841.
64. Lohmann, C.; Hilwel, S.; Galla, H. J. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Target., 2002, 10, 263-276.
65. Prieto, P.; Blaauboer, B. J.; de Boer, A. G.; Boveri, M.; Cecchelli, R.; Clemedson, C.; Coecke, S.; Forsby, A.; Galla, H. J.; Garberg, P.; Greenwood, J.; Price, A.; Tähti, H. Blood-brain barrier in vitro models and their application in toxicology. The report and recommendations of ECVAM Workshop 49. Altern. Lab Anim., 2004, 32, 37-50.
66. Patel M. M.; Goyal, B. R.; Bhadada S. V.; Bhatt, J. S.; Amin A. F. Getting into the brain. Approaches to enhance brain drug delivery. CNS Drugs, 2009, 23(1), 35-58.
67. Pardridge, W. M. Recent advances in blood brain-barrier transport. Annu. Rev. Pharmacol. Toxicol., 1988, 28, 25-39.
68. Jamal, T.; Scherrmann, J. M.; Rees, A. R.; Kaczorek, M. Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm. Sci. Technol. Today., 2000, 3, 155-162.
69. Greig, N. H. Drug delivery to the brain by blood-barrier: circumvention and drug modification. In: Neuwelt, E.A., Ed. Implications of the blood-brain barrier and its manipulation. Plenum Press: New York, 1989, pp. 311-367.
70. Sawynok, J. The therapeutic use of heroin: a review of the pharmacological literature. Can. J. Physiol. Pharmacol., 1986, 64, 1-6.
71. Pardridge, W. M. Blood-brain barrier delivery. Drug Discov. Today. 2007, 12, 54-61.
72. Pardridge, W. M.; Mietus, L. J. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin bound hormone. J. Clin. Invest., 1979, 64, 145-154.
73. Lesniak, M. S. Novel advances in drug delivery to brain cancer. Technol. Cancer Res. Treat. 2005, 4, 417-28.
74. Albrecht, K. W.; de Witt, P. C.; Leenstra, S.; Bakker, P.J.M.; Beijnen, J.H.; Troost, D.; Kaaijk, P.; Bosch, A.D. High concentration of daunorubicin anddaunorubicin in human malignant astrocytomas after systemic administration of liposomal daunorubicin. J. Neurooncol., 2001, 53, 267-271.
75. Koukourakis, M. I.; Koukouraki, S.; Fezoulidis, I.; Kelekis, N.; Kyrias, G.; Archimandritis, S.; Karkaritsas, N. High intratumoural accumulation of stealth liposomal doxorubicin (caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer, 2000, 83, 1281-1286.
76. Pardridge, W. M. Brain drug targeting: the future of brain drug development. Cambridge University Press: Cambridge 2001.
77. Bundgaard, H. Means to enhance penetration: 1Prodrugs as a mean to improve the delivery of peptide drugs. Adv. Drug Deliv. Rev., 1992, 8, 1-38.
78. Stella, V. Prodrugs: an overview and definition. In: Huguchi, T.; Stella, V. J. Eds. Prodrugs as novel drug delivery systems. ACS Symposium Series 14, Am. Chem Soc., Washington DC, 1975, pp. 1-115.
79. Stella, V. The control of drug delivery via bioreversible modification. In Juliano R (eds) Drug Delivery Systems, Characteristics and biomedical Applications. Oxford Uniersity Press, New York, 1980, pp. 112-175.
80. Notari, E. Prodrug design. Pharmacol. Ther., 1981, 14, 25-53.
81. Sinkula, A.; Yalkowsky, S. Rationale for design of biologically reversible drug derivatives: Prodrugs. J. Pharm. Sci., 1975, 27, 665-673.
82. Wermuth, C. Designing prodrugs and bioprecursors. In: Jolles, G.; Wooldribge, K., Eds. Drug Design: Fact or Fantasy? Academic, New York 1984, pp. 47-72.
83. McClure, D. The effects of a prodrug of epinephrine (dipivalylepinephrine) in glaucoma- General pharmacology, toxicology and clinical experience. In: Higuchi, T.; Stella, V., Eds. Prodrugs as Novel Drug Delivery Systems. American Chemical Society Symposium Series 14, American Chemical Society, Washington DC, 1975, pp. 224-235.
84. Hamilton-Miller, J. Chemical manipulations of the penicillin nucleus: A review. Chemotherapia. 1967, 12, 73-88.
85. Bodor, N. Drug targeting and retrometabolic drug design approaches. Adv. Drug Deliv. Rev., 1994, 14, 157-66.
86. Bodor, N.; Buchwald, P. Drug targeting via retrometabolic approaches. Pharmacol. Ther., 1997, 76, 1-27.
87. Terasaki, T.; Tsuji, A. Drug delivery to the brain utilizing blood brain barrier transport systems. J. Control Release, 1994, 29, 163-169.
88. Cornford, E. M.; Diep, C. P.; Pardridge, W. M. Blood brain barrier transport of valproic acid. J. Neurochem., 1985, 44, 1541-1550.
89. Boyle, F. M.; Eller, S. L.; Grossman, S. A. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neurol. Oncol., 2004, 6, 300-305.
90. Murata, M.; Tamai, I.; Kato, H.; Nagata, O.; Tsuji, A. Efflux transport of a new quinolone antibacterial agent, HSR-903 across the Blood Brain Barrier. J. Pharmacol. Exp. Ther., 1999, 290, 51-57.
91. Pardridge, W. M. New approaches to drug delivery through the blood-brain barrier. Trends Biotechnol., 1994, 12, 239-245.
92. Kang, Y. S.; Pardridge, W. M. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Pharm. Res., 1994, 11, 1257-1264.
93. Pardridge, W. M.; Triguero, D.; Buciak, J. L. Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. Endocrinology, 1990, 126, 977-984.
94. Koehler-Stec, E. M.; Simpson, I. A.; Vannucci, S. J.; Landschulz, K. T.; Landschulz, W.H. Monocarboxylate transporter expression in mouse brain. Am. J. Physiol., 1998, 275, E516-E524.
95. Kido, Y.; Tamai, I.; Okamoto, M.; Suzuki, F.; Tsuji, A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm. Res., 2000, 17, 55.
96. Deguchi, Y.; Nozama, K.; Yamada, S.; Yokoyama, Y.; Kimura, R. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis. J. Pharmacol. Exp. Ther., 1996, 280, 551-560.
97. Cornford, E.M.; Hyman, S. Blood brain permeability to small and large molecules. Adv. Drug Deliv. Rev., 2000, 36, 145-163.
98. Oldendorf, W.H. Carrier mediated blood brain barrier transport of short chain monocarboxylic organic acids. Am. J. Physiol., 1973, 224, 1450-1453.
99. Terasaki, T.; Takakuma, S.; Moritani, S.; Tsuji, A. Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. J. Pharmacol. Exp. Ther., 1991, 258, 932.
100. Poole, R.C.; Halestrap, A.P. Hepatic and extrahepatic insulin action in humans: measurement in the absence of non-steady-state error. Am. J. Physiol., 1993, 264, E761.
101. Jain, A.; Chourasia, M. K.; Soni, V.; Jain, N. K.; Khare, P.; Gupta, Y.; Jain, S. K. Brain Specific Delivery of Rifampicin from Lactyl Stearate Coupled Liposomes via Monocarboxylic Acid Transporters. Am. J. Drug Deliv., 2006, 4(1), 1-8.
102. Khare, P.; Jain, A.; Soni, V.; Jain, N. K.; Jain, S. K. Glutamate coupled liposomes of dopamine HCL for effective management of Parkinsonism's. J. Drug Deliv. Sci. Tech., 2009, 63(5), 372-379.
103. Oldendorf, W. H. Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol., 1971, 221, 1629-1639.
104. Gupta, Y.; Soni, V.; Chourasia, M. K.; Jain, A.; Khare, P.; Jain, S. K. Targeted oriented drug delivery to the brain via transferring coupled liposomes. Drug Deliv. Technol., 2005, 5, 66-71.
105. Duffy, K. R.; Pardridge, W. M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res., 1987, 420, 32-38.
106. Holly, J.; Perks, C. The role of insulin-like growth factor binding proteins. Neuroendocrinology, 2006, 83, 154-160.
107. Triguero, D.; Buciak, J.; Pardridge, W. M. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem., 1990, 54, 1882-1888.
108. Shin, S. U.; Friden, P.; Moran, M.; Olson, T.; Kang, Y. S.; Pardridge, W. M.; Morrison, S. L. Transferrin-antibody fusion proteins are effective in brain targeting. Proc. Natl. Acad. Sci. USA, 1995, 92, 2820-2824.
109. Jain, A.; Jain, S. K. PEGylation: An approach for Drug Delivery. A Review. Crit. Rev. Ther. Drug Carrier Syst., 2008, 25(5), 403-444.
110. Kreuter, J. Nanoparticlate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
111. Gulyaev, A. E.; Gelperina, S. E.; Skidan, I. N.; Antropov, A. S.; Kivman, G. Y.; Kreuter, J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res., 1999, 16, 1564-1569.
112. Friese, A.; Seiller, E.; Quack, G.; Lorenz, B.; Kreuter, J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor ant agonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm., 2000, 49, 103-109.
113. Kreuter, J.; Alyautdin, R. N.; Kharkevich, D. A.; Ivanov, A. A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674, 171-174.
114. Lockman P. R.; Mumper, R. J.; Khan, M. A.; Allen, D. D. Nanoparticle technology for delivery of drugs across the blood-brain barrier. Drug Dev. Indus. Pharm., 2002, 28, 1-13.
115. Kaur, I. P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release, 2008, 127, 97-109.
116. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx., 2005, 2, 3-14.
117. Derossi, D.; Chassaing, G.; Prochiantz, A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol., 1998, 8, 84-87.
118. Jamal, T.; Scherrmann, J. M.; Rees, A. R.; Kaczorek, M. Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm. Sci. Technol. Today, 2000, 3, 155-162.
119. Rousselle, C.; Clair, P.; Lefauconnier, J. M.; Kaczorek, M.; Scherrmann, J. M.; Temsamani, J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol., 2000, 57, 679-686.
120. Salahuddin, T. S.; Johansson, B. B.; Kalimo, H.; Olsson, Y. Structural Changes in the rat brain after carotid infusions of hyperosmolar solutions: an electron microscopic study. Acta Neuropathol., 1988, 77, 5-13.
121. Lossinsky, A. S.; Vorbrodt, A. W.; Wisniewski, H. M. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J. Neurocytol., 1995, 24, 795-806.
122. Broman, T. On basic aspects of the blood-brain barrier. Acta Psychiatr. Neurol. Scand., 1955, 30(1-2), 115-124.
123. Arthur, F. E.; Shivers, R. R.; Bowman, P. D. Astrocyte-mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Dev. Brain Res., 1987, 36, 155-159.
124. Pardridge, W.M. CNS drug design based principles of blood-brain barrier transport. J. Neurochem., 1998, 70, 1781-1792.
125. Kroll, R. A.; Neuwelt, E. A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery, 1998, 42, 1083-100.
126. Salahuddin, T. S.; Johansson, B. B.; Kalimo, H.; Olsson, Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol. Appl. Neurobiol. Neuropept., 1988, 14, 467-482.
127. Miller, G. Drug targeting: breaking down barriers. Science, 2002, 297, 1116-1118.
128. Sakamoto, A.; Ido, T. Liposome targeting to rat brain: effect of osmotic opening of the blood-brain barrier. Brain Res., 1993, 629, 171-175.
129. Olivier, J. C. Drug transport to brain with targeted nanoparticles. NeuroRX, 2005, 2, 108-119.
130. De Jong, W. H.; Borm, P. J. A. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed., 2008, 3, 133-149.
131. Matsukado, K.; Inamura, T.; Nakano, S.; Fukui, M.; Bartus, R.T.; Black, K.L. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of the bradykinin analog, RMP-7. Neurosurgery, 1996, 39, 125-133.
132. Huynh, G. H.; Deen, D. F.; Szoka Jr, F. C. Barriers to carrier mediated drug and gene delivery to brain tumors. J. Control. Release, 2006, 110, 236-259.
133. Saija, A.; Princi, P.; Trombetta, D.; Lanza, M.; De Pasquale, A. Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat. Exp. Brain Res., 1997, 115, 546-551.
134. Hanig, J. P.; Morrison Jr, J. M.; Krop, S. Ethanol enhancement of bloodbrain barrier permeability to catecholamines in chicks. Eur. J. Pharmacol., 1972, 18, 79-82.
135. Azmin, M. N.; Stuart, J. F.; Florence, A. T. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother. Pharmacol., 1985, 14, 238-242.
136. Zhang, Y.; Miller, D. W. Pathways for drug delivery to the central nervous system. In: Wang, B.; Siahaan, T.; Soltero, R. A., Eds. Drug delivery: principles and applications. New Jersey (NJ): Wiley Interscience, 2005, pp. 29-56.
137. Erdlenbruch, B.; Alipour, M.; Fricker, G.; Miller, D. S.; Kugler, W.; Eibl, H.; Lakomek, M. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br. J. Pharm., 2003, 140, 1201-1210.
138. Erdlenbruch, B.; Jendrossek, V.; Eibl, H.; Max, L. Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats. Exp. Brain Res., 2000, 135, 417-422.
139. Erdlenbruch, B.; Jendrossek, V.; Kugler, W.; Eibl, H.; Lakomek, M. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother. Pharmacol., 2002, 50, 299-304.
140. Erdlenbruch, B.; Schinkhof, C.; Kugler, W.; Heinemann, D. E. H.; Herms, J.; Eibl, H.; Lakomek, M. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br. J. Pharm., 2003, 139, 685-694.
141. Pardridge, W. M.; Kang, Y. S.; Buciak, J. L.; Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res., 1995, 12, 807-816.
142. Wu, D.; Yang, J.; Pardridge, W. M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest., 1997, 100, 1804-1812.
143. Boiardi, A.; Eoli, M.; Pozzi, A.; Salmaggi, A.; Broggi, G. Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. Ital. J. Neurol. Sci., 1999, 20, 43-48.
144. Morantz, R. A.; Kimler, B. F.; Vats, T. S.; Henderson, S. D. Bleomycin and brain tumors: a review. J. Neurooncol., 1983, 1, 249-255.
145. Scheld, W. M. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. Rev. Infect. Dis., 1989, 11 (Suppl. 7), S1669-S1690.
146. Giussani, C.; Carrabba, G.; Pluderi, M.; Lucini, V.; Pannacci, M.; Caronzolo, D.; Costa, F.; Minotti, M.; Tomei, G.; Villani, R.; Carroll, R. S.; Bikfalvi, A.; Bello, L. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. Cancer Res., 2003, 63, 2499-2505.
147. Dang, W.; Colvin, O. M.; Brem, H.; Saltzman, W. M. Covalent coupling of methotrexate dextran enhances the penetration of cytotoxicity into a tissue like matrix. Cancer Res., 1994, 54, 1729-1735.
148. Benoit, J. P.; Faisant, N.; Venier-Julienne, M. C.; Menei, P. Development of microspheres for neurological disorders: from basics to clinical applications. J. Control. Release, 2000, 65, 285-296.
149. Menei, P.; Jadaud, E.; Faisant, N.; Celle, M. B.; Michalak, S.; Fournier, D.; Delhaye, M.; Benoit, J. P. Stereotaxic implantation of 5-fluorouracilreleasing microspheres in malignant glioma. Cancer. 2004, 100, 405-410.
150. Fung, L. K.; Ewend, M. G.; Sills, A.; Sipos, E. P.; Thompson, R.; Watts, M.; Colvin, O. M.; Brem, H.; Saltzman, W. M. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res., 1998, 58(4), 672-684.
151. Leong, K. W.; Brott, B. C.; Langer, R. Bioerodible polyanhydrides as drugcarrier matrices: I. Characterization, degradation, and release characteristics. J. Biomed. Mater. Res., 1985, 19, 941-955.
152. Brem, H.; Gabikian, P. Biodegradable polymer implants to treat brain tumors. J. Control. Release, 2001, 74, 63-67.
153. Misra, A. N.; Ganesh, S.; Shahiwala, A. Drug delivery to the central nervous system: a review. J. Pharm. Pharmaceut. Sci., 2003, 6, 252-273.
154. Gennuso, R.; Spigelman, M. K.; Chinol, M.; Zappulla, R. A.; Nieves, J.; Vallabhajosula, S.; Paciucci, P. A.; Goldsmith, S. J.; Holland, J. F. Effect of blood brain barrier and blood tumor barrier modification on central nervous system liposomal uptake. Cancer Invest., 1992, 11, 118-128.
155. Soni, V.; Jain, A.; Khare, P.; Gulbake, A.; Jain, S. K. Potential approaches for Drug Delivery to Brain: Past, Present and Future. Crit. Rev. Ther. Drug Carrier Syst., 2010, 27(3), 187-236.
156. Umezawa, F.; Eto, Y. Liposome targeting to mouse brain: man nose as a recognition marker. Biochem. Biophys. Res. Commun., 1988, 153, 1038-1044.
157. Pardridge, W. M. Tyrosine hydroxylase replacement in experimental parkinson's disease with transvascular gene therapy. NeuroRx., 2005, 2, 129-138.
158. Noble, C. O.; Krauze, M. T.; Drummond, D. C.; Yamashita, Y.; Saito, R.; Berger, M. S.; Kirpotin, D. B.; Bankiewicz, K. S.; Parl, J. W. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res., 2006, 66, 2801-2806.
159. Schmidt, J.; Metselaar, J. M.; Wauben, M. H.; Tokya, K. V.; Storm, G.; Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, 1895-1904.
160. Koukourakis, M. I.; Koukouraki, S.; Giatromanolaki, A.; Kakolyris, S.; Georgoulias, V.; Velidaki, A.; Archimandritis, S.; Karkaritsas, N.N. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: rationale for combination with radiotherapy. Acta Oncol., 2000, 39, 207-211.
161. Hau, P.; Fabel, K.; Baumgart, U.; Rümmele, P.; Grauer, O.; Bock, M. A.; Dietmaier, C.; Dietmaier, W.; Dietrich, J.; Dudel, C.; Hübner, F.; Jauch, T.; Drechsel, E.; Kleiter, I.; Wismeth, C.; Zellner, A.; Brawanski, A.; Steinbrecher, A.; Marienhagen, J.; Bogdahn, U. PEGylated liposomal doxorubicin efficacy in patients with recurrent high-grade gloma. Cancer, 2004, 100, 1199-1207.
162. Omori, N.; Maruyama, K.; Jin, G.; Wang, S. J.; Hamakawa, Y.; Sato, K.; Nagano, I.; Shoji, M.; Abe, K. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol. Res., 2003, 25, 275-279.
163. Kreuter, J.; Alyautdin, R. N.; Kharkevich, D. A.; Ivanov, A. A. Passage of peptides through the blood brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674, 171-174.
164. Kreuter, J.; Gelperina, S. Use of nanoparticles for cerebral cancer. Tumori, 2008, 94, 271-277.
165. Ricci, M.; Blasi, P.; Giovagnoli, S.; Rossi, C. Delivery drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue. Curr. Med. Chem., 2006, 13, 1757-1775.
166. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, A. M.; Forni, F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release, 2005, 108, 84-96.
167. Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Vergoni, A. V.; Tacchi, R.; Bertolini, A.; Vandelli, M. A.; Forni, F. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J. Control. Release, 2007, 122, 1-9.
168. Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59, 454-477.
169. Gabizon, A.; Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin rationale for use in solid tumours. Drugs. 1997, 54 (Suppl. 4), 15-21.
170. Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Zheng, C. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release, 1999, 59, 299-307.
171. Koziara, J. M.; Lockman, P. R.; Allen, D. D.; Mumper, R. J. In situ bloodbrain barrier transport of nanoparticles. Pharm. Res., 2003, 20, 1772-1778.
172. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. Poly (ethylene glycol)-polyethyleneimine nanogel particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf. B Biointerfaces, 1999, 16, 291-304.
173. Vinogradov, S. V.; Bronich, T. K.; Kabanov, A. V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev., 2002, 54, 135-147.
174. Vinogradov, S. V.; Zeman, A. D.; Batrakova, E. V. Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Release, 2005, 107, 143-157.
175. D'Emanuele, A.; Attwood, D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev., 2005, 57, 2147-2162.
176. Boas, U.; Heegaard, P. M. Dendrimers in drug research. Chem. Soc. Rev., 2004, 33, 43-63.
177. Huang, R. Q.; Ying-Hua, Qu.; Wei-Lun, Ke.; Jian-Hua, Zhu.; Yuan-Ying, Pei.; Chen, J. Efficient gene delivery targeted to the brain using a transferrinconjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J., 2007, 21, 1117-1125.
178. Madrid, Y.; Langer, L. F.; Brem, H.; Langer, R. New directions in the delivery of drugs and other substances to the central nervous system. Adv. Pharmacol., 1991, 22, 299-324.
179. Leigh, K.; Elisevich, K.; Rogers, K.A. Vascularization and microvascular permeability in solid versus cellsuspension embryonic neural grafts. J. Neurosurg., 1994, 81(2), 272-283.
180. Snyder, E.Y.; Senut, M. C. The use of non neuronal cells for gene delivery. Neurobiol. Dis., 1997, 4, 69-102.
181. Santini, Jr, J. T.; Cima, M. J.; Langer, R. A controlled-release microchip. Nature. 1999, 397, 335-338.
182. Thorne, R. G.; Emory, C. R.; Ala, T. A.; Frey, W. H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res., 1995, 692, 278-282.
183. Born, J.; Lange, T.; Kern, W. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci., 2002, 5, 514-516.
184. Illum, L. Nasal drug delivery: new development strategies. Drug Discov. Today, 2002, 7, 1184-1189.
185. Wang, X.; He, H.; Leng, W.; Tang, X. Evaluation of brain targeting for the nasal delivery of estradiol by the microdialysis method. Int. J. Pharm., 2006, 317, 40-46.
186. Buchwald, P.; Bodor, N. A simple, predictive, structure- based skin permeability model. J. Pharm. Pharmacol., 2001, 53, 1087-1098.
187. Krewson, C. E.; Klarman, M. L.; Saltzman, W. M. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res., 1995, 680, 196-206.
188. Temsamani, J.; Scherrmann, J.M.; Rees, A. R.; Kaczorek, M. Brain drug delivery technologies: novel approaches for transporting therapeutics. Res. Focus, 2000, 5(3), 155-162.
189. Boyd, S.R.; Tan, D.S.W.; Souza, L.De.; Neale, M.H.; Myatt, N.E.; Alexander, R.A.; Robb, M.; Hungerford, J.L.; Cree, I.A. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br. J. Ophthalmol., 2002, 86, 440-447.